Morphocell Technologies is a regenerative medicine company developing stem cell–derived engineered tissues for severe liver disease and other organ deficiencies. Its platform is based on allogeneic iPSC-derived engineered tissues, and the company’s lead efforts are centered on ReLiver and related approaches to organ replacement therapy. Morphocell positions itself as a preclinical-to-development-stage cell therapy company rather than a conventional small-molecule biotech.